Daily Ards Research Analysis
Three impactful ARDS-related studies span clinical trials and translational science. A pediatric septic shock RCT shows that targeting the 5th centile mean blood pressure is non-inferior for mortality and reduces vasopressor exposure and ARDS prevalence. A multicenter stepped-wedge RCT found no reduction in prone-position pressure ulcers with a standardized bundle, while a murine study shows IV exosome therapy outperforms intranasal/nebulized routes in acute lung injury.
Summary
Three impactful ARDS-related studies span clinical trials and translational science. A pediatric septic shock RCT shows that targeting the 5th centile mean blood pressure is non-inferior for mortality and reduces vasopressor exposure and ARDS prevalence. A multicenter stepped-wedge RCT found no reduction in prone-position pressure ulcers with a standardized bundle, while a murine study shows IV exosome therapy outperforms intranasal/nebulized routes in acute lung injury.
Research Themes
- Pediatric septic shock hemodynamic targets and ARDS outcomes
- Prone positioning nursing bundles and pressure ulcer prevention in ARDS
- Extracellular vesicle (exosome) therapy and delivery routes in acute lung injury
Selected Articles
1. Fifth Centile Versus 50th Centile Mean Blood Pressure Targets in Pediatric Septic Shock: A Randomized Controlled Trial.
In a single-center randomized noninferiority trial (n=144) of pediatric septic shock, targeting the 5th centile MBP was non-inferior to the 50th centile for 28-day mortality. The lower MBP target reduced norepinephrine exposure, vasoactive duration and score, and was associated with lower ARDS prevalence, without differences in length of stay, ventilation, CRRT, or adverse events.
Impact: Addresses a key gap in pediatric sepsis guidelines by directly testing competing blood pressure targets. Demonstrates potential to reduce vasopressor exposure and ARDS without harming survival.
Clinical Implications: Lower MBP targets (5th centile) may be safely adopted to minimize vasopressor burden and potentially reduce ARDS in pediatric septic shock, pending confirmation in multicenter trials.
Key Findings
- 28-day mortality did not differ between MBP targets (16.9% vs 23.2%; p=0.41).
- Norepinephrine use was higher with the 50th centile target (85% vs 67%; p=0.04).
- Vasoactive duration and Vasoactive-Inotropic Score were higher with the 50th centile target (30.4 ± 13.3 vs 18.8 ± 10.8 hours; p=0.001; VIS 64.0 ± 35.7 vs 45.2 ± 29.6; p=0.001).
- ARDS prevalence was higher with the 50th centile target (32.8% vs 16.9%; p=0.02); other secondary outcomes showed no significant differences.
Methodological Strengths
- Randomized noninferiority design with prespecified primary and secondary outcomes
- Objective clinical endpoints including mortality and ARDS prevalence
Limitations
- Single-center, open-label design may limit generalizability and introduce performance bias
- Sample size modest; not powered for rare adverse events or long-term outcomes
Future Directions: Multicenter, blinded RCTs comparing personalized hemodynamic targets and evaluating long-term neurodevelopmental and organ failure outcomes.
OBJECTIVES: Hypotension is common in septic children, mean blood pressure (MBP) guides vasoactive agent titration. However, the Surviving Sepsis Guidelines for children were unable to recommend whether to target the 5th or 50th MBP percentile for septic shock. We aim to compare two MBP targets (5th vs. 50th percentile) for titrating vasoactive agents in septic shock patients. DESIGN: Single-center, open-label, randomized noninferiority trial. SETTING: It was conducted in a tertiary care PICU in In
2. A Bundle of Interventions to Prevent Pressure Ulcers During Prone Position in Adult Patients With Acute Respiratory Distress Syndrome: Results of a French Stepped-Wedge Randomized Controlled Trial.
In the ESCARD multicenter stepped-wedge RCT (n=156 analyzed), a standardized bundle to prevent pressure ulcers during prone positioning in moderate-to-severe ARDS did not significantly reduce new anterior pressure ulcers at Day 7 compared with usual care. Intervention adherence was high (91.8%), but inter-rater discrepancy in ulcer staging was substantial (42.8%).
Impact: Provides rigorous, negative evidence against a commonly advocated nursing bundle for prone ARDS, highlighting the need to refine prevention strategies and measurement standards.
Clinical Implications: Routine adoption of this specific bundle may not reduce pressure ulcers in prone ARDS; units should standardize ulcer assessment and consider alternative or augmented strategies.
Key Findings
- High fidelity to the six-component bundle during the intervention period (91.8% vs 1.2% at first proning).
- No significant reduction in new anterior pressure ulcers at Day 7 (odds ratio 0.92; 95% CI 0.39–2.18).
- Substantial 42.8% discrepancy between blinded expert assessors in ulcer staging.
- Trial registered (NCT03125421) with multicenter implementation across 9 ICUs; COVID-19 caused a temporary interruption.
Methodological Strengths
- Stepped-wedge randomized multicenter design with high implementation fidelity
- Blinded outcome assessment using standardized photographs
Limitations
- Potential underpowering for modest effect sizes; heterogeneous usual care across centers
- High inter-rater variability in ulcer staging complicates outcome measurement
Future Directions: Develop validated, reproducible ulcer assessment tools and test alternative bundles (e.g., advanced surfaces, pressure mapping) in larger cluster-RCTs.
BACKGROUND: In patients with moderate-to-severe acute respiratory distress syndrome, the frequency of pressure ulcers is higher in the prone position than in the supine position. AIM: To assess the effect of a bundle of interventions to prevent pressure ulcers in patients with acute respiratory distress syndrome prone. STUDY DESIGN: ESCARD is a stepped-wedge prospective multicentre trial conducted in France that included patients with moderate-to-severe acute respiratory distress syndrome, intu
3. Comparison of efficacy of exosomes derived from human umbilical cord blood mesenchymal stem cells in treating mouse acute lung injury via different routes.
In LPS-induced ALI mice, hUCMSC-derived exosomes reduced histologic lung inflammation and lowered TNF-α, IL-6, and IL-1β in serum and BALF across routes, with intravenous delivery outperforming intranasal and nebulized routes at a tested dose of 5×10^8 particles. Nebulized low-dose treatment showed limited efficacy.
Impact: Demonstrates route-dependent efficacy of exosome therapy in ALI, a key translational consideration for future ARDS interventions.
Clinical Implications: While preclinical, findings support prioritizing intravenous delivery in early human studies of exosome-based therapies for lung injury and inform dose/route optimization.
Key Findings
- hUCMSC-Exo reduced alveolar inflammatory cell infiltration, hemorrhage, and edema in LPS-induced ALI histopathology.
- Exosome treatment decreased TNF-α, IL-6, and IL-1β in serum and BALF.
- Intravenous delivery at 5×10^8 particles achieved superior therapeutic effects compared with intranasal and nebulized routes; nebulized low-dose was minimally effective.
Methodological Strengths
- Direct comparison of multiple administration routes and doses in the same ALI model
- Multimodal outcome assessment (histology and cytokines in serum and BALF)
Limitations
- Preclinical murine model limits generalizability to humans
- Sample size per group and long-term outcomes were not reported in the abstract
Future Directions: Evaluate pharmacokinetics, biodistribution, and safety of IV exosomes in large-animal models, followed by dose-finding human trials with mechanistic biomarkers.
OBJECTIVE: To investigate the therapeutic efficacy of human umbilical cord blood mesenchymal stem cell-derived exosomes (hUCMSC-Exo) in a lipopolysaccharide (LPS)-induced acute lung injury (ALI) mouse model and compare the effects of different administration routes. METHODS: An ALI mouse model was established through intratracheal LPS injection. Mice received hUCMSC-Exo through tail vein injection, nasal drip, or atomization at 4-and-24 h post-modeling, with comparisons made across low, medium,